Revance agrees to lower take-private offer by Crown Labs

(Reuters) -Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics (NASDAQ:RVNC) at a roughly 50% lower price compared to an original agreement signed in August, the companies said on…